Drug Watch

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.

Merck presents promising Phase 1 trial results for MK-2214, a novel Alzheimer treatment, showcasing its potential to slow disease progression.

Incannex Healthcare's PSX-001 shows promise in treating generalized anxiety disorder, offering innovative, effective solutions beyond traditional therapies.

Bristol Myers Squibb expands patient enrollment in the ADEPT-2 study, exploring Cobenfy's potential for treating Alzheimer disease-related psychosis.

Check out the pipeline updates from November!

Otsuka Pharmaceutical submits a new drug application for centanafadine for treatment of ADHD, showing significant efficacy across all age groups.

Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a favorable safety profile and potential for rapid relief.

Explore the unique benefits of Ingrezza, a VMAT2 inhibitor for tardive dyskinesia, and how it compares to other treatment options.

Tonmya, a groundbreaking fibromyalgia treatment, is now available in the US, offering hope for millions suffering from chronic pain.

Silo Pharma partners with Allucent to advance SPC-15, a novel treatment for PTSD, aiming for FDA approval and addressing unmet patient needs.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

New phase 4 data reveals Austedo significantly reduces involuntary movements and enhances quality of life for adults with tardive dyskinesia.

Caplyta, now FDA-approved as an adjunctive therapy for major depressive disorder, offers rapid relief and a favorable safety profile for patients. Learn more from Suresh Durgam, MD, the primary investigator.

Neurocrine's NBI-1070770 fails to meet primary endpoint in phase 2 trial for major depressive disorder, prompting further analysis of results.

AtaiBeckley reveals promising phase 2b open-label extension study results for BPL-003, showing sustained antidepressant effects in patients with treatment-resistant depression after redosing.

Roger S. McIntyre, MD, FRCPC, shares how FDA approval of Caplyta will benefit patients with major depressive disorder

Johnson & Johnson's Caplyta gains FDA approval as an adjunctive treatment for major depressive disorder, offering hope for improved patient outcomes.

Axsome Therapeutics advances AXS-05 for Alzheimer disease agitation, showing significant improvement in clinical trials and addressing critical patient needs.

Check out the pipeline updates from October!

Cingulate's CTx-1301 shows promising phase 3 results for ADHD, offering effective once-daily dosing and potential FDA approval by 2026.

New analysis reveals Ingrezza's 40 mg dose significantly improves tardive dyskinesia symptoms, showcasing long-term efficacy and safety in patients.